
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
https://www.pharmacytimes.org/on-demand/a-managed-care-review-approaches-to-mitigate-blindness-associated-with-neovascular-agerelated-macular-degeneration





